88例卵巢上皮性癌行ATP-TCA体外药敏试验结果分析

该研究是探讨三磷酸腺苷生物荧光肿瘤抗癌药物药敏性分析实验（ATP-TCA）在卵巢癌患者化疗中的应用。研究选取88例卵巢上皮性癌新鲜组织行ATP-TCA体外药敏试验,分析结果、计算各种化疗药物敏感性,并与48例对照组患者进行临床近期有效率的比较。结果显示,在体外药敏试验敏感性最强的单药为紫杉醇（51.9%）,敏感性强弱依次为：紫杉醇〉卡铂〉顺铂〉吉西他滨〉拓泊替康〉多西他赛〉依托泊苷〉环磷酰胺〉博来霉素,联合用药方案敏感性较单药增加。药敏组患者临床近期有效率（85.23%）高于对照（68.75%）。ATP-TCA是一种有效的抗癌药物敏感性分析实验,可为卵巢癌患者临床化疗提供个体化的指导方案。

Analysis Results of ATP-Tumor Chemosensitivity Assay In Vitro of 88 Cases of Epithelial Ovarian Cancer

In this research, we demonstrated the feasibility of ovarian cancer patients in clinical individualized chemotherapy using ATP-tumor chemosensitivity assay （ATP-TCA） in vitro. We examined the heterogeneity of chemosensitivity in ovarian cancer specimens （n=88） using an ex vivo ATP-TCA. The short-term effectiveness of chemotherapy was compared between ATP group and control group. We found that the most active single agent tested was paclitaxel, to which 51.9% of samples were sensitive. The order of the sensitivity is paclitaxel 〉 carboplatin 〉 cisplatin 〉 gemcitabine 〉 topotecan 〉 docetaxel 〉 etoposide 〉 cyclophosphamide 〉 bleomycin. Combinations of agents showed more strong sensitivity cases. The short-term effectiveness rates in ATP group （85.23%） and control group （68.75%） were significantly different. Chemosensitivity testing may provide a practical method of testing new regimens before clinical trials in ovarian cancer patients.